Toronto Dominion Bank Raises Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Toronto Dominion Bank increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.5% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 5,207 shares of the biotechnology company’s stock after purchasing an additional 75 shares during the quarter. Toronto Dominion Bank’s holdings in Repligen were worth $656,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Andra AP fonden purchased a new stake in shares of Repligen in the 2nd quarter worth approximately $25,000. YHB Investment Advisors Inc. acquired a new stake in Repligen in the first quarter valued at approximately $26,000. International Assets Investment Management LLC acquired a new position in shares of Repligen during the second quarter worth $33,000. Lazard Asset Management LLC increased its position in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new stake in Repligen in the second quarter worth about $57,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and lowered their target price for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Guggenheim assumed coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Finally, Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Insider Activity

In other news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $148.82 on Tuesday. The business has a fifty day moving average of $148.80 and a two-hundred day moving average of $153.15. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.32 billion, a price-to-earnings ratio of 595.28, a price-to-earnings-growth ratio of 4.23 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 earnings per share. As a group, research analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.